AmCad BioMed Corporation (TPEX:4188)

AmCad BioMed Revenue

AmCad BioMed had revenue of 6.72M TWD in the quarter ending June 30, 2026, a decrease of -17.66%. This brings the company's total for the last twelve months to 28.60M, down -34.39% year-over-year. In the year 2025, AmCad BioMed had annual revenue of 30.44M, down -42.69%. That makes AmCad BioMed the 43,800th largest company in the world by revenue and 2,165th in Taiwan.

• Revenue (ttm): 28.60M
• Revenue Growth: -34.39%
• P/S Ratio: 34.10
• Revenue / Employee: 841.26K
• Employees: 34
• Market Cap: 975.33M

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

Chart

• Precise Medical Devices 21.31M 70.0%
• Medical Diagnostic Software 9.13M 30.0%

By Geography

Chart

• Taiwan 12.48M 41.0%
• Europe 8.76M 28.8%
• Asia (excluding Taiwan, and China) 7.52M 24.7%
• China 1.29M 4.2%
• Overseas 384.00K 1.3%

Fiscal year ended Dec 31, 2025 See the full AmCad BioMed breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	30.44M	-22.67M	-42.69%
Dec 31, 2024	53.11M	-12.15M	-18.62%
Dec 31, 2023	65.26M	3.63M	5.88%
Dec 31, 2022	61.63M	-24.16M	-28.16%
Dec 31, 2021	85.79M	21.85M	34.17%

Data Source: S&P Global Market Intelligence Last updated: Aug 7, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 30, 2026

Data Sources Report a data error